Please assess the completion status of the following clinical trial:

Trial Title: Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed c-MET pathway dysregulation.~* Advanced hepatocellular carcinoma which could not be suitable for treatment with locoregional therapies or has progressed following locoregional therapy.~* Measurable disease as determined by RECIST version 1.1.~* Current cirrhotic status of Child-Pugh class A with no encephalopathy.~* Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2.~Exclusion Criteria:~* Received any prior systemic chemotherapy or molecular-targeted therapy for hepatocellular carcinoma such as sorafenib.~* Previous treatment with c-MET inhibitor or hepatocyte growth factor targeting therapy.~* Previous local therapy completed less than 4 weeks prior to dosing and, if present, any acute toxicity \> grade 1.~* Known active bleeding (e.g. bleeding from gastro-intestinal ulcers or esophageal varices) within 2 months prior to screening or with history or evidence of inherited bleeding diathesis or coagulopathy.~* Clinically significant venous or arterial thrombotic disease within past 6 months.~* History of acute or chronic pancreatitis, surgery of pancreas or any risk factors that may increase risk of pancreatitis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- INC280 (Type: EXPERIMENTAL): The protocol consisted of two independent parts (Dose-Determining Part and Dose Expansion Part). Patients were treated with INC280 300 mg twice a day in the Dose-Determining Part. The dose for the Expansion Part could be lower, equal or higher than in the Dose-Determining Part and was determined after the Dose Determining Part at the dose decision analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).